At prese”t, The polymeric micelle paclitaxel (Genexol-PM) has been approved and marketed in China for the first-line treatment of epidermal growth factor receptor (EGFR) mutation-negative and anaplastic lymphoma kinase (ALK)-negative, non-surgically resectable, locally advanced or metastatic non-small-cell lung cancer (NSCLC) and has become the first domestically marketed paclitaxel micellar formulation [158,159]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.